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a b s t r a c t
Previously, we reported that specific lower dose of sodium 2,3-dimercapto-1-propanesulfonic acid
(DMPS) which is an antidote to heavy metal intoxication, inversely enhanced cisplatin (CDDP)-induced
antitumor activity to S-180 cell-bearing mouse. This activity was only weak with meso-2,3-
dimercaptosuccinic acid (DMSA), however. This study investigated the effects of lower doses of DMPS
or DMSA on the nephrotoxicity and kinetics of CDDP. Kidney and blood isolated from female mice which
received CDDP with or without DMPS or DMSA once daily for 4 days were provided for measuring levels
of blood urea nitrogen (BUN) and transporter proteins (OCT2: organic cation transporter; MATE1:
multidrug and toxin extrusion) mRNA, and CDDP-originated platinum, and TUNEL staining of renal
tubular cells. DMPS or DMSA reduced effectively CDDP-induced BUN, and caused a moderate reduction
of platinum in kidney. Additionally, both dimercapto-compounds restored the CDDP-reduced mRNA
levels of transporter proteins (OCT2 and MATE1), and apparently suppressed the CDDP-induced
apoptosis. These results suggest that DMPS, as well as DMSA, at approximate 17-fold dose (mmol/kg)
of CDDP, has an enough potential to reverse the CDDP nephrotoxicity, and concomitant use of DMPS
considering both dose and timing for administration is potentially useful for preventing nephrotoxicity
and enhancing antitumor activity during CDDP chemotherapy.
© 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
1. Introduction
Cisplatin (cis-diammine-dichloroplatinum; CDDP), an inorganic
platinum complex has been evaluated as a most available chemo-
therapeutic drug for various types of malignant tumors.1e4 How-
ever, CDDP-induced nephrotoxicity is a major limitation to CDDP-
based chemotherapy.5 The causes of the renal toxicity appeared
to be due to the accumulation of CDDP in the kidneys followed by
apoptosis of renal tubular cells.6 Apoptosis induced by CDDP seems
to be based on mitochondria-dependent and -independent path-
ways,7 partly through the activation of caspase-3.8 Further, CDDP-
generated oxidant stress also appears to contribute to the
apoptosis of renal tubular cells.9 On the other hand, several reports
offered an aspect that CDDP impaired the function of transporters
on the renal tubular cell membranes to be resulted in renal cu-
mulative uptake of CDDP.10,11 Major transporters involved in the
uptake and excretion of CDDP in the renal tubular cells are organic
cation transporter (OCT) family and multi drug and toxin extrusion
(MATE) family. In these transporters, OCT2 and MATE1 play sig-
nificant roles in excretion of BUN or metabolites of drugs.12e14 The
OCT family is driven electrogenetically by inside-negative mem-
brane potentials, consequently taking diverse organic cations into
renal tubular cells.15 In contrast, the MATE family, which mediates
the exchange of organic cations with hydrogen ions in renal brush-
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border membranes, is suggested to be responsible for the final step
of urinary excretion of cationic drugs including CDDP.16,17
Dithiol metal chelators such as 2,3-dimercapto-1-
propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic
acid (DMSA) are generally considered suitable for treating cases
of heavy metal poisoning, including those caused by lead,18 mer-
cury,19,20 cadmium,21,22 and copper.23 In the previous report, we
showed that DMPS, but not DMSA, synergistically enhanced the
antitumor activity of CDDP with 1.4-fold efficacy, only when two
drugs were administered at an adequate dose ratio and time in-
terval.24 However, when DMPS enhanced the antitumor effects of
CDDP, it is not clear how DMPS influenced to the nephrotoxicity.
The present study, by means of examining the changes of BUN,
kinetics of platinum, expression of cation transporter genes and
apoptosis of renal tubular cells, investigated the ability of DMPS to
protect renal tissue against CDDP-induced toxicity at lower doses
which enhanced antitumor effect of CDDP, while comparing to the
potency of DMSA.
2. Materials and methods
2.1. Animals
Female SPF ddy-mice weighing 25e30 g were purchased from
Japan SLC (Hamamatsu, Japan). The animals were group-housed in
laboratory cages with wood chips in an air-conditioned room
(temperature 23 ± 2 C, humidity 55 ± 5%, and lighting
6:00 ame6:00 pm) and maintained on commercial laboratory
chow andwater ad libitum for oneweek before the experiments. All
things used for the animals were sterilized by autoclaving or radi-
ation. All animals received humane care in accordance with the
Guidelines for the Treatment of Experimental Animals approved by
Tokyo Dental College and the Japanese Pharmacological Society.
(Approval Number: 250702).
2.2. Chemicals
CDDP, DMPS and DMSA were purchased from SigmaeAldrich
(St. Louis, MO, U.S.A.). PCR primers and the SUPERSCRIPT First-
Strand Synthesis System for RT-PCR containing reverse transcrip-
tase (RTase) (Superscript™ III, RNase H), dithiothreitol (DTT),
oligo(dT)12e18 primer, deoxynucleosidetriphosphate (dNTP),
RNase H, DNase I, and RNase inhibitor were purchased from Invi-
trogen (San Diego, CA, U.S.A.). NucleoSpin RNAII was obtained from
MACHEREYNAGEL GmbH & Co. (Duren, Germany). The DyNAmo
SYBER green qPCR Kit was obtained from Finnzymes (Espoo,
Finland), and the DNA 1000 Lab Chips Kit (Agilent Technologies,
Palo Alto, CA, U.S.A.) was obtained from Takara Bio Co. (Tokyo,
Japan). All other reagents used were of the highest grade
commercially available.
2.3. Preparation and administration of CDDP, DMPS and DMSA
CDDP was dissolved in 0.9% sodium chloride solution acidified
at pH 3.0 with hydrochloride inwater bath at 60 C. DMPS or DMSA
was dissolved in physiological saline or 0.9% sodium chloride so-
lution alkalinized with 0.5% NaHCO3, respectively. All agents which
were prepared immediately before use were administered to each
animal with a volume of 0.1 ml/10 g body weight. Untreated ani-
mals which received no drug stress were given a vehicle used for
solubilizing CDDP and DMPS or DMSA.
The details of drug administration and sampling for the BUN
measurement, platinum kinetics, transporter gene analysis and
TUNEL staining analysis was described in Fig. 1.
2.4. Measurement of BUN
On 5th and 7th day after the initial administration of drugs,
blood sample was collected 100e150 ml through a glass capillary
tube inserted into orbital venous plexus under pentobarbital
anesthesia. In order to take serum more than 50 ml, these samples
were centrifuged at 4 C, for 5 min, at 12,000 g. The BUN concen-
tration was determined by the diacetylmonoxime method using
assay kits purchase from the Wako Pure Chemical Industries.
2.5. Measurement of platinum
On 5th, 7th and 9th day after the initial administration of drugs,
blood sample was collected as well as in the BUN measurement,
and then kidney was isolated immediately after sacrificing by over
dose of anesthesia. In order to take plasma, blood samples were
immediately heparinized in the ice-cold tubes and centrifuged for
10 min, 12,000 g at 4 C. The excised kidneys and plasma were
sonicated 10min in 70% HNO3 with 50 mg/ml Iridium (Ir) as internal
standard. Each sample was diluted 500-fold by ultrapure water
(Milli Q Millipore Japan). The amount of platinum was determined
using the ICP-MS (inductively coupled plasma-mass spectrometry;
Agilent 7500 CS, U.S.A.).
2.6. Quantitative RT-PCR
Specimen for DNA was obtained from kidney removed at 1 h,
2 h, 6 h, 12 h after the final administration with CDDP ± DMPS or
DMSA. After treatment of total RNAwith DNase I, first-strand cDNA
was synthesized using Oligo(dT)12e18 primers and Superscript™
III RNase Hreverse transcriptase. Gene expression of OCT2 and
MATE1 was determined by using the b-actin gene (GenBank
accession number NM_007393.3) as an internal control and
primers specific for OCT2 mRNA (accession number NM_013667.2)
(upper primer, AGT GGC CTA TGC CCT TCC; lower primer, TGG AGA
CTC CGG TAT GCA C; product size, 100 base pairs), MATE1 mRNA
(NM_026183.5) (upper primer, GCT CTT TGC TGTGAC CTT CTG;
lower primer, GAT CAC TTG AGC CAC CAA GG; product size, 106
base pairs). The cDNA was amplified by real-time quantitative PCR
using the DyNAmo SYBER green qPCR Kit (Finnzymes) on the DNA
Engine Opticon 2 System (Bio-Rad Laboratories; Hercules, CA,
U.S.A.), running 48 cycles of the following protocol: 15 min pre-
denaturation at 95 C, 10-s denaturation at 94 C, 20-s annealing at
59.0 C for b-actin, OCT2, MATE1, followed by a 30-s extension at
Fig. 1. Time schedule for drug administration and collecting specimen. (a) showed that
drugs were repetitively administered once daily for 4 days. The administration of CDDP
was performed 1 h after pretreatment with DMPS or DMSA. CDDP was administered at
5.7 mmol/kg, s.c. for each time point in all experiments. DMPS and DMSA were
administered at 50, 100 and 250 mmol/kg, s.c. for the BUN measurement, whereas for
other experiment, the dose was limited to 100 mmol/kg, s.c. (b) showed the sampling
time for the assay of BUN, qRT-PCR and TUNEL staining and (c), for platinum isolation
in kidney and plasma.
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72 C. The PCR products were separated with the Agilent 2100
Bioanalyzer (Agilent Technologies, U.S.A.), which utilizes chip-
based nucleic acid separation technology. Furthermore, identifica-
tion of the amplified PCR products of the OCT2, MATE1 and b-actin
cDNAs was performed by dye terminator cycle sequencing.
2.7. Evaluation of apoptosis by TUNEL staining
Kidneys were fixed in 10% formalin in PBS, embedded in
paraffin, and sectioned in thickness of 4.0 mm. Each section was
stained with terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) staining to assess the apoptosis
that is induced with tissue damage. TUNEL staining was performed
using an In situ Apoptosis Detection Kit (Takara Bio, Inc., Shiga,
Japan). A Zeiss Axiophot 2 microscope (Carl Zeiss Imaging Solu-
tions, GmbH, Munich, Germany) was used for immunofluorescence
microscopy (TUNEL staining). Images were captured using a chilled
three-chip color charge-coupled-device camera and digitized using
image analysis software (AxioVision Rel. 4.6.3.0; Carl Zeiss Imaging
Solutions).
2.8. Statistical analysis
The results are given as the meanwith standard deviation (S.D.)
of data. When a significant difference among more than three
groups was obtained in the KruskaleWallis H test, SteeleDwass
post hoc test was applied to determine the significant pairwise
differences. A P-value <0.05 was considered as reaching statistical
significance.
3. Results
3.1. The effects of DMPS and DMSA on protection against CDDP-
induced renal dysfunction
CDDP increased the serum BUN levels by 87% and 61%
comparing with the untreated group on both 5th and 7th day,
respectively (Fig. 2AeD). DMPS at doses of 50e250 mmol/kg, i.p.
prevented these changes in a dose-dependent manner with a
maximum 41% decrease comparingwith the CDDP alone on 7th day
(Fig. 2A and B). The recovering effect in the DMPS-pretreated group
indicated almost the same level of BUN as in the control group. On
the other hand, DMSA completely inhibited CDDP-induced change
with all doses at 50e250 mmol/kg, i.p. on both 5th and 7th day
(Fig. 2C and D).
3.2. The effects of DMPS and DMSA on protection against CDDP-
induced apoptosis in renal tubular cells
As shown in Fig. 3, immunohistochemical observations after
staining of renal section with TUNEL made apparent apoptotic cells
in the renal tubules of animals treated with CDDP (5.7 mmol/kg/day
for 4 days) comparing to the untreated control (Fig. 3A and B). It
was noteworthy that in the concomitant administration of DMPS or
Fig. 2. Effect of DMPS (A, B) and DMSA (C, D) pretreated against the increase of BUN by CDDP. CDDP at 5.7 mmol/kg with or without both dimercapto-compounds were administered
once daily for 4 days. On day 5 and 7, BUN were measured. Data were shown by mean ± S.D. of 6 mice per group. Statistically significant differences (*p < 0.05 vs the untreated
group, #p < 0.05 vs the CDDP control group) are indicated.
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DMSA (100 mmol/kg/day for 4 days), TUNEL-stained cells were not
found at all. Thus, both dimercapto-compounds revealed protective
effects against the CDDP-induced apoptosis in renal tissues.
3.3. The mRNA expression of transporters: OCT2 and MATE1
As shown in Fig. 4, CDDP generally did not cause major changes
in both transporter mRNA levels. Precisely, CDDP gave inhibitory
effects with significant decrease (by 24%) in the MATE1 mRNA
levels only on 5th day. Then those phenomena continued with
weak suppressive tendency (around 20% lower) also on 7th day
(Fig. 4B). On the other hand, the OCT2 mRNA levels were hardly
affected by CDDP on both days (Fig. 4A). When DMPS and DMSA
were administered concomitantly with CDDP, both mRNA levels on
both days were not changed at all comparing to the untreated
control. Both dimercapto-compounds completely reversed the
transporter production suppressed by CDDP.
3.4. Kinetics of platinum as CDDP in kidney and blood plasma
CDDP 5.7 mmol/kg, s.c. singular or combination with either
DMPS or DMSA (100 mmol/kg, s.c. for each) was administered once
daily for 4 days. To detect accumulation of CDDP in the kidney and
blood plasma, platinumwas quantitatively measured by ICP-MS on
5th, 7th and 9th day. As shown in Fig. 5A, the platinum concen-
trations in the kidney were kept at higher levels without decrease
in the CDDP alone group through the experiment. In contrast, the
pretreatment with either DMPS or DMSA reduced platinum levels
in a time-dependentmannerwith the significant decrease of 25% or
27%, respectively, on 9th day compared with on 5th day. In plasma
(Fig. 5B), platinum concentrations in all of CDDP alone and DMPS-
and DMSA-pretreated groups rapidly decreased in a time-
dependent manner, whereas there were no significant differences
between those groups in each day. Thus, it is demonstrated that
DMPS and DMSA contributed to the gradual excretion of platinum
from the kidney without a dramatic decrease like in plasma.
4. Discussion
This study investigated that the pretreatment with DMPS at a
lower dose, which complied with the optimal dose ratio of DMPS to
CDDP, produced not only the reinforcement of the anticancer ac-
tivity24 but also the protective effects, as well as DMSA, to the renal
function. In the previous report, we demonstrated that when CDDP
and DMPS were concomitantly administered at the adequate dose
ratio and time interval, the antitumor activity of CDDP was
strengthened in a maximum.24 The maximal potentiating effects of
DMPS on the antitumor activity of CDDP occurred at a dose ratio of
Fig. 3. Evaluation of apoptosis by TUNEL staining. TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-fluorescein nick end labeling; a cell apoptosis marker, green
signal) and DAPI (4,6-diamidino-2-phenylindole; a marker of cell nuclei, blue signal) in paraffin-embedded kidney sections from each group on 7th day. TUNEL-positive nuclei were
observed the CDDP alone. Scale bar: 20 mm. The number of animals used for morphological study was 3 mice for each group.
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100 mmol/kg, s.c. to 5.7 mmol/kg, s.c., and the favorable time interval
for administration of DMPS was 1 h before CDDP. On the other
hand, DMSA did not show an augmentative effect on antitumor
activity of CDDP.24
In the several researches for the purpose of reducing nephro-
toxicity of CDDP, some derivatives of dimercapto-compounds have
been applied for recovering of the renal function injured by
CDDP.20,25e28 DMSA and DMPS, more beneficial compounds, are
featured by less toxic, easily soluble to water, more stable at the pH
of the body than prototype such as dimercaprol (BAL: British Anti-
Lewisite).29 Some researches provided the effectiveness of those
agents on removing platinum or palliating the severity of renal
function.25e28 As their researches were focused to extrude plat-
inum from the kidney following the CDDP administration, the
doses of dimercapto-compounds were set in much higher levels
(e.g. 1000e2000 mmol/kg, i.v.)27,28 compared with our setting
(100 mmol/kg, s.c.). The group of Graziano et al succeeded in
reducing renal platinum by 50% from the kidney by treatment with
DMSA (550e1100 mmol/kg, i.p.) after CDDP (20 mmol/kg, i.v.)
administration.25 The doses of dimercapto-compounds used in
their experiment were approximately 5e10 times higher than that
in our experiment. Moreover, the dose of CDDP used in our
experiment was therapeutically relevant and less than in other
researches. Practically, the total dose (for 4 days) of CDDP was
approximately 2.7 fold of intravenous dosage recommended in the
guideline for cisplatin dosage (for 5days) in Japan, while it was
about one third or a half in other experiments.25,26 Furthermore,
Graziano et al25 presented that the treatment of DMSA more than
3 h after CDDP failed to prevent renal toxicity. Planas-Bohne et al26
also referred to the necessity to select a reasonable time for
Fig. 4. The mRNA expression of OCT2 and MATE1. The mRNA expression of OCT2 (A) and MATE1 (B) on 5th and 7th day after single administration of CDDP 5.7 mmol/kg with or
without DMPS, DMSA 100 mmol/kg. Data are shown by mean ± S.D. of 6 mice per group. Statistically significant differences (*p < 0.05 vs the untreated group) are indicated.
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between CDDP injection and the start of treatment for DMPS and
DMSA. Those deduced that optimal order and time interval for
treatment of chelating agents was necessary to elicit a more
excellent effect to CDDP detoxification. In our experiment, the 1 h
time interval between the start of pretreatment with chelating
agents and CDDP was critical for effectively detoxifying CDDP-
induced nephrotoxicity. Thus, our experiment was characterized
by distinctive experimental design as follows: therapeutically
relevant dose of CDDP; lower doses of DMPS and DMSA; pre-
treatment with DMPS and DMSA 1 h before CDDP administration.
Then, to certify that DMPS exerts not only enhancement of
CDDP-induced antitumor activity but also reduction of CDDP-
induced nephrotoxicity, we examined whether the lower doses
(50, 100, 250 mmol/kg) of DMPS or DMSA effectively reverse the
nephrotoxicity caused by CDDP (5.7 mmol/kg). Against the BUN
levels raised by CDDP, DMPS reduced them in a time- and a dose-
dependent manner with complete normalizing at 100 mmol/kg on
7th day, while DMSA reversed by 5th day at all doses. From these
results, DMPS, as well as DMSA, seems to be an available agent for
relief of nephrotoxicity. CDDP toxicity has been attributed to a
number of molecular processes as DNA damage,30,31 mitochondrial
damage,7,32 caspase activation,8,33 formation of reactive oxygen
species,34,35 apoptosis and necrosis.36e38 Some of researches re-
ported that CDDP-induced renal injury was resulted from CDDP-
generated apoptosis. That is, the cause of the increase in BUN
was considered to be due to renal tubule cell death brought about
by apoptosis. Therefore, it is very meaningful to investigate the
effects of dimercapto-compounds on CDDP-induced apoptosis.
Apoptosis in the kidney was assessed by using the TUNEL assay.
Total dose of 22.8 mmol/kg of CDDP slightly increased the number
of apoptotic nuclei compared with the control group. DMPS and
DMSA at 100 mmol/kg completely suppressed CDDP-induced
apoptotic degeneration on the nuclei of renal tubular cells. Thus,
it was demonstrated that both dimercapto-compounds sufficiently
and efficiently alleviate CDDP-induced renal failure even at lower
doses. Furthermore, these findings strongly supported our
Fig. 5. Platinum accumulation in kidney and plasma. Platinum accumulation in kidney (A) and plasma (B) on the day 5, 7, or 9 after CDDP 5.7 mmol/kg with or without DMPS, DMSA
100 mmol/kg. Data are the mean ± S.D. of 6 mice per group. Statistically significant differences (*p < 0.05) are indicated.
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tentative theory that DMPS at lower dose exert protective actions
on the CDDP-induced nephrotoxicity. So, we obtained interesting
findings on the kinetics of platinum (CDDP) in the kidney and
plasma. In plasma, platinum concentration in each group of CDDP
with/without DMPS or DMSA showed remarkable decrease in a
time-dependent manner with one fifth-fold less on 9th day than
on 5th day in all groups. Moreover, DMPS and DMSA gave no in-
fluence on enhancement of decreasing platinum in plasma. In the
kidney, on the contrary, DMPS and DMSA promoted excretion of
platinum, although with a little efficacy and with slow velocity,
remaining 70e80% levels of platinum on 9th day comparing with
on 5th day. Consequently, it is noteworthy that although quite a bit
of platinum remained in the kidney of mouse pretreated with
DMPS or DMSA, the renal function (BUN levels) was almost
entirely reversed (as shown in the results of BUN levels), and was
relieved from intoxication of CDDP. Transport system on the renal
tubular cell membrane involved in the uptake and extrusion of
drugs or other metabolites was provided by several researches: a
permeable glycoprotein (P-gp) ABC family and organic ion trans-
porter subtypes such as organic anion transporter (OAT1, 2, 3, OAT-
K1), organic anion transporting polypeptide (OATP-1), OCT2, and
MATE family. Of these transporters, OCT2 and MATE1 are pre-
dominantly involved in transport of CDDP, and contribute to up-
take into and extrusion out of cells, respectively.15 CDDP
suppressed the expression of mRNA of MATE1 but a little on OCT2.
On the other hand, DMPS and DMSA completely returned them to
the normal level. These transporters have specificity to trans-
porting organic cations exclusively. Then, CDDP as an inorganic
cation was not easily transported via OCT2, an exclusive trans-
porter for organic cations. Those things indicated that both
transporters slightly contributed to transcellular movement of
platinum in the kidney. These results indicated that although
transporter regained normal function, CDDP was not effectively
extruded from the kidney, but the velocity was very slow. Yokoo39
proposed that CDDP as an inorganic cation is hard to be trans-
ported via OCT2, because of specificity of exclusively transporting
organic cations. So, from our findings, it is speculated that CDDP
retained in tissue is inactivated by forming complex with DMPS or
DMSA to be nontoxic state. Moreover, CDDP-DMPS and -DMSAwill
be chemical forms easily to be transported through OCT2 and
MATE1.
Verschraagen et al40 presented that the high concentration of
mercapto-compound (monothiol ligand) in the kidney inactivated
CDDP by forming nontoxic platinum complexes. In general, com-
pounds including dithiol ligand like DMPS or DMSA, possessing
stronger coordination binding force, favor to react with heavy
metals and result in forming CDDP-DMPS and CDDP-DMSA ad-
ducts. Accordingly, it has been thought to be theoretically proper
that DMPS and DMSA greatly contributed to form the inactive and
nontoxic platinum complexes, moreover, DMPS-CDDP or DMSA-
CDDP adducts formed in the cells neutralized the nephrotoxicity
of CDDP. Thus, it is indicated that lower dose of DMPS greatly helps
not only increment of CDDP-induced antitumor activity but also
decrement of CDDP-induced renal failure. Further investigations
will need to be carried out to understand the extracellular excretion
mechanism of complex compounds via transporter or membrane
transport and the pharmacokinetics of intracellular CDDP and
DMPS. We conclude that DMPS administered under the adequate
condition on the dose and the time interval to CDDP exerts the
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